SLEEP DISRUPTION IN CHILDREN AND ADOLESCENTS WITH EPILEPSY: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Authors: Alice A Winsor\textsuperscript{a,b}, MSc; Caroline Richards\textsuperscript{b}, PhD; Stacey Bissell, PhD\textsuperscript{b}; Stefano Seri\textsuperscript{c}, MD; Ashley Liew\textsuperscript{d}, MRCPsych; Andrew P Bagshaw\textsuperscript{a,b}, PhD.

\textsuperscript{a}Centre for Human Brain Health, University of Birmingham, UK.
\textsuperscript{b}School of Psychology, University of Birmingham, UK.
\textsuperscript{c}Birmingham Children’s Hospital, Birmingham Women’s and Children’s Hospital NHS Foundation, UK.
\textsuperscript{d}Evelina London Children’s Hospital; South London and Maudsley NHS Foundation Trust; University of Warwick; University of Birmingham UK.

Corresponding Author:
Alice Winsor
Centre for Human Brain Health
School of Psychology
University of Birmingham
B15 2SA
Email: aaw423@bham.ac.uk
Telephone: 0121 414 6261

Figures:
Number of figures: 6

Tables:
Number of tables: 3

Supplementary information:
Total items of supplementary information: 1
SUMMARY

This systematic review and meta-analysis aims to assess and quantify putative differences in sleep architecture, sleep efficiency, sleep timing and broadly-defined sleep difficulties between children with and without epilepsy. Databases were searched systematically, and studies identified in PubMed, EMBASE, PsychINFO and Medline. The meta-analysis included 19 studies comparing a total of 901 children with epilepsy to 1470 healthy children. Relative to healthy children, children with epilepsy experienced reduced sleep time, sleeping on average 34 minutes less across self-report, actigraphy, 24-hour video-EEG and polysomnography measures. They had more sleep difficulties specifically in the domains of night waking, parasomnias and sleep disordered breathing. The analysis also revealed a significantly increased percentage of N2 sleep and decreased sleep efficiency in children with epilepsy compared to healthy children. These results illustrate that children with epilepsy are vulnerable to more sleep difficulties compared to healthy children. This suggests that screening for sleep difficulties should be an integral part in a diagnosis of epilepsy to ensure that clinically relevant sleep difficulties are identified and treated. Such an approach may ultimately aid in the development of treatment strategies which can contribute to improvements in both developmental and diagnostic outcomes for children with epilepsy.

Keywords: Epilepsy, Sleep, Children, Adolescents, Meta-analysis
Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AASM</td>
<td>American Academy of Sleep Medicine</td>
</tr>
<tr>
<td>AED</td>
<td>Antiepileptic drug</td>
</tr>
<tr>
<td>CSHQ</td>
<td>Children’s sleep habits questionnaire</td>
</tr>
<tr>
<td>CWE</td>
<td>Children with epilepsy</td>
</tr>
<tr>
<td>EEG</td>
<td>Electroencephalography</td>
</tr>
<tr>
<td>ID</td>
<td>Intellectual disability</td>
</tr>
<tr>
<td>IED</td>
<td>Interictal epileptiform discharges</td>
</tr>
<tr>
<td>NREM</td>
<td>Non-rapid eye movement sleep</td>
</tr>
<tr>
<td>PDSS</td>
<td>Paediatric daytime sleepiness scale</td>
</tr>
<tr>
<td>PRISM</td>
<td>Preferred Reporting Items for Systematic reviews and Meta-analyses</td>
</tr>
<tr>
<td>PSG</td>
<td>Polysomnography</td>
</tr>
<tr>
<td>PSQ</td>
<td>Paediatric sleep questionnaire</td>
</tr>
<tr>
<td>QOL</td>
<td>Quality of life</td>
</tr>
<tr>
<td>R&amp;K</td>
<td>Rechtschaffen &amp; Kales</td>
</tr>
<tr>
<td>REM</td>
<td>Rapid eye movement sleep</td>
</tr>
<tr>
<td>SBQ</td>
<td>Sleep behaviour questionnaire</td>
</tr>
<tr>
<td>SE</td>
<td>Sleep efficiency</td>
</tr>
<tr>
<td>SDB</td>
<td>Standardised mean difference</td>
</tr>
<tr>
<td>TST</td>
<td>Total sleep time</td>
</tr>
</tbody>
</table>
INTRODUCTION

Epilepsy is the most frequently occurring neurological disease in childhood and often presents in early development [1]. While the primary clinical issue is seizures, over the years there has been an increased focus on the role of sleep in people with epilepsy, and its impact on overall well-being as well as its link with seizures. In order to accurately quantify the differences between children with epilepsy (CWE) and healthy children, it is essential to assess a variety of sleep parameters (e.g., sleep timing, sleep efficiency, sleep architecture and sleep difficulties) to achieve a complete picture.

For the purpose of this meta-analysis, sleep difficulties are defined as a combination of diagnosable clinical sleep disorders (e.g., insomnia) and/or components of diagnosable sleep disorders (e.g., difficulties settling to sleep) measured by widely used instruments. The prevalence of such sleep difficulties in healthy children and adolescents is estimated to range between 25 – 40%, with common presentations including night waking and bedtime resistance [2,3]. These rates are significantly higher in CWE than in healthy children, irrespective of whether seizures occur during sleep [4]. Existing observational studies demonstrate that sleep difficulties such as excessive daytime sleepiness, night awakenings and reduced sleep duration are more common in CWE than healthy children [5,6,7] and that these difficulties can appear very early in the epilepsy trajectory [8].

Similarly, polysomnography (PSG) has demonstrated differences in sleep architecture at a macro-structural level with reductions in REM sleep, increased sleep latency and frequent shifting of sleep stages [9,10] reported in CWE compared to healthy children. Abnormalities in sleep micro-structure are also reported in CWE. In particular, seizure type can be associated with severity of sleep difficulty, as evidenced by greater reduction in sleep spindles in patients with secondary generalised seizures compared to patients with focal seizures [11].
The bidirectional association between sleep and epilepsy is underpinned by various mechanisms, which are more and less well understood and are reviewed in detail elsewhere [12,13,14]. Its impact can extend beyond neurological and physiological changes to impact overall wellbeing, including poor cognitive and behavioural outcomes [8,15], problems with reading and writing [16], attentional deficits [17] and difficulties managing emotions [18]. CWE experience considerable negative psychological and social consequences, which can be partially attributed to underlying sleep disturbances, highlighting the need for clinical acknowledgement. Moreover, a recent randomised controlled trial found the use of a sleep intervention during hospital visits resulted in improvements in sleep quality and sleep duration in CWE, compared to those who did not receive the intervention [19]. These results illustrate that sleep habits can be modified. An accurate quantification of the nature and range of sleep difficulties experienced by CWE is therefore potentially beneficial to help design interventions which can ameliorate negative clinical, psychological and social outcomes in this group.

Although previous research has investigated the association between sleep and epilepsy in children, to our knowledge no meta-analysis has been conducted to characterise the types of sleep difficulties present in this population in reference to healthy children. We aim to synthesise and collate previous studies investigating sleep parameters in CWE compared to healthy children in order to quantify these differences.

This meta-analysis was conducted with the following goals:

i. To assess differences in sleep timing, sleep efficiency, sleep architecture and sleep difficulties in CWE compared to healthy children

ii. To assess heterogeneity between studies and provide recommendations in order to reduce between-study heterogeneity for future research
iii. To examine possible moderators for differences in sleep timing, efficiency, architecture and difficulties between CWE and healthy children including method of sleep assessment, quality of study and demographic variables including sex and age.

METHODS

We performed a systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines [20].

**Search strategy**

A systematic literature search was conducted using the databases Medline, Embase, PsychINFO and PubMed in April 2019. Examples of key terms used included “sleep” OR “sleep problem*” OR “sleep disturbance” AND “Epilep*” OR “Epilepsy” OR “Paediatric Epilepsy” AND “child*” OR “adolescen*” (see Table 1 for a full list of search terms).

Study selection

Selection of papers for inclusion in the review was conducted by AW. Figure 1 illustrates the search process and results. The initial literature search returned 14,951 papers. After duplicates were removed 8838 papers were screened via the titles and abstracts. Papers that met the following criteria at this stage of eligibility screening were included for further review: 1) available in English, 2) reported on paediatric patients with epilepsy and included a measure of sleep 3) not animal studies 4) not review articles, case studies, editorials, letters or comments 5) reported on children or adolescents aged ≤18 years 6) sample size > 5. Following the eligibility screening, the full text articles of the remaining studies were retrieved and screened against these...
criteria and the following additional inclusion criteria: 1) No intellectual disability (ID) 2) Suitable data to extract for pooling of effect sizes (i.e. measures of means and SDs) 3) Inclusion of a healthy control group.

Data Extraction and Quality Review

Nineteen papers met the eligibility criteria at full text screening and were included in the final analyses. Data extraction was performed by AW. A quality criteria checklist adapted from previous meta-analyses [21,22] was used to review the overall quality of studies (see Table 2). Each study was reviewed for their sample identification, instruments used to measure sleep and epilepsy classification based on a scale of 0 to 3 (poor to excellent). Each score was coded with a colour, 0 was coded as red for a poor score, 1 as orange for an adequate score, 2 as yellow for a good score and 3 as green for an excellent score. This resulted in a total score between 0-9. The total score was then divided by the maximum possible score of 9 to produce a quality value between 0 and 1.

Two authors (AW and SB) reviewed the quality of each paper independently and inter-rater reliability was established using weighted Cohen’s kappa statistic. Inter-rater reliability of the two authors was excellent for the overall scale (Kappa= 0.95, p<.001). The individual item ratings varied between good (epilepsy diagnosis, Kappa=0.81, p<.001), almost perfect (sample identification, Kappa=0.87, p<.001) and perfect agreement (sleep measurement, Kappa=1, p<.001)
Sleep measures

The sleep parameters of interest were: 1) TST 2) Sleep difficulties 3) Sleep efficiency and 4) Sleep architecture. TST was measured with a combination of methods including PSG, 24-hour video-electroencephalography (EEG), actigraphy and self-report. Sleep difficulties in the retrieved papers were assessed via two questionnaires. The Children’s Sleep Habits Questionnaire (CSHQ) [23] is a parent report sleep measure. It consists of a global score and eight additional subscales, where higher scores are indicative of more severe sleep difficulties. A separate analysis was conducted using the subscales ‘parasomnias’, ‘sleep disordered breathing (SDB)’, ‘sleep onset delay’, ‘sleep duration’, ‘bedtime resistance’, ‘night wakings’, ‘sleep anxiety’ and ‘daytime sleepiness’. Other studies used the Sleep Behaviour Questionnaire (SBQ) [18] which is also a parent report questionnaire designed to measure duration and quality of sleep. It consists of a global score and 5 subscales: ‘parasomnias’, ‘parent/child interaction’, ‘sleep fragmentation’, ‘daytime drowsiness’ and ‘bedtime difficulties’, where higher scores are again indicative of more frequent sleep difficulties. Note that the SBQ and the CSHQ were initially treated separately, after which a subgroup analysis was conducted. This did not reveal significant differences, indicating that the type of questionnaire did not contribute substantially to the results. They were subsequently combined into one composite analysis for overall sleep difficulties. Sleep efficiency was measured via a combination of PSG and actigraphy. Finally, sleep architecture was measured via PSG and 24-hour video-EEG, as the only methods capable of providing this information.

Statistical analyses

All statistical analyses were performed in R, version 3.6.0 with RStudio, using the meta and metafor packages. Standard deviations and means for each of the sleep parameters across CWE and control groups were inputted into a spreadsheet. Separate meta-analyses were conducted to
produce pooled overall effect size estimates for sleep timing, sleep difficulties, sleep architecture and sleep efficiency. Each pooled effect size was expressed as a standardised mean difference (SMD, Hedge’s g) with corresponding 95% confidence intervals. All analyses were computed using a random effect model. This model assumes that the true effect size varies between studies for two reasons: 1) sampling error within the studies and 2) differences in study population which result in real differences in effect size between studies [24]. It was therefore beneficial to use this model, given the range of participant characteristics across all studies, such as age and diagnoses of patient. For all analyses we used the Sidik-Jonkman estimator rather than the DerSimonian-Laird estimator which can lead to false positives when heterogeneity is high, and number of studies are low [25], which was the case in our sample.

Cochrane’s Q was used to assess whether there was statistically significant between-study heterogeneity present in the analysis. The amount of heterogeneity present was then quantified using Higgins I² with cut off values placed at 0, 25%, 50% and 75% corresponding to ‘no’, ‘moderate’, ‘substantial’ and ‘high’ heterogeneity [26]. Between-study heterogeneity was explored when possible through subgroup analyses and meta-regressions in a mixed effect model across different variables, which were established a priori. The purpose of this was to understand whether the methodological approach of the studies had an impact on the overall results. Type of sleep instrument e.g., PSG, 24-hour video-EEG, actigraphy or questionnaire, was used as the categorical variable in the subgroup analyses. Meta-regression analyses were performed using age (years), sex (male %) and study quality score as continuous variables.

The robustness of the results was assessed in sensitivity analyses using outlier removal and the leave-one-out method, where, as studies are omitted one at a time, effect sizes are recalculated to assess the influence of individual studies on the overall effect size estimate. Risk of publication bias was assessed using visual inspection of contour-enhanced funnel plots, which plot standardised mean difference (Hedges g) in the x-axis against standard error, as a measure
for size of studies in the y-axis. Statistical testing for funnel plots was conducted using the
Eggers test, and only for analyses consisting of 10 studies or more as the power of the test is too
low to detect reliable bias estimates with less [27].

RESULTS

Study characteristics

Nineteen studies met the inclusion criteria and were used to assess the differences in sleep
parameters between a total of 901 CWE with a mean age of 10.8 years (reported in 17 studies)
and 1470 healthy children with a mean age of 10.8 years (reported in 17 studies). Nine studies
used PSG to assess sleep parameters, of which three [9,30,37] used an adaptation night (data
were reported for only the second night across all these studies), six [28,32,33,34,38,39] used
one night of sleep only with no adaptation night and one study used 24-hour video-EEG [36]. Of
the remaining nine studies, eight [6,8,16,18,29,31,40,41] used parent reported sleep
questionnaires and one [35] used both actigraphy and questionnaires. Table 3 presents
characteristics of the studies included in the meta-analysis.

Total sleep time

Of the 12 studies that reported TST in CWE in comparison to healthy children, six studies
reported TST via PSG, one via 24-hour video-EEG, one used actigraphy and four used self-
reported sleep time. The study by Barreto et al. (2002) [28] consisted of two subgroups:
‘idiopathic generalised epilepsy’ and ‘idiopathic focal epilepsy’. They were initially treated with
two separate analyses in order to avoid unit of analysis error. One subgroup (‘idiopathic focal
epilepsy’) was revealed to be an outlier in subsequent sensitivity analysis so was not included in
the meta-analysis for TST. Two studies were conducted by Gogou et al (2016, 2017) [33,34]
using the same control group. In this case, the ‘focal and generalised epilepsy’ group was kept in
the analysis as it had a larger sample size than the ‘rolandic epilepsy’ group, which was omitted.

The random effects model revealed that CWE experienced significantly shorter TST in
collection to healthy children (SMD= -0.55, [95% CI -1.08; -0.02] p=0.04), see Figure 2).
Mean weighted difference comparison found that CWE slept on average 34 minutes less than
healthy controls, and this ranged between 151 minutes less to 9 minutes more. Significantly high
heterogeneity among the studies was detected (Q= 62.34, I²=82.4%, p<0.01). The robustness of
the results was tested via outlier and sensitivity analysis by the leave one out method, which
revealed no influential cases.

Sleep difficulties

Nine studies were pooled into the meta-analysis for sleep difficulties. Five measured sleep
difficulties via the total scores on CSHQ and four via the SBQ. The random effects model for the
full sample initially revealed a non-significant effect (SMD= 2.08, 95% CI [-0.53, 4.69], p=0.10)
and substantial heterogeneity I²=97.3%, Q=299.44, p<0.01. Leave one out sensitivity analysis
and outlier analysis revealed that the study by Batista et al. (2007) [29] was an outlier as
evidenced by clear distortion on the effect size estimate. This outlier was removed, and the
random effects model was computed again and found to yield a significant result (SMD= 0.97,
95% CI [0.48, 1.46], p=0.002, see Figure 3) with reduced heterogeneity I²= 88.1%, Q=59.04,
p<0.01. This indicated that CWE suffer significantly more frequent and severe sleep difficulties
compared to healthy children. Batista et al. (2007) [29] was excluded in further analysis.

Type of sleep difficulties
A separate analysis was conducted on studies measuring sleep difficulties via the CSHQ, taking advantage of the subscales which examine different aspects of sleep difficulties. Each subscale of the questionnaire was separated as eight different outcomes and one total outcome to conduct subgroup analyses (see Figure 4). We found that CWE had significantly higher scores on the following subscales: night waking (SMD=0.42, 95% CI [0.16; 0.68], p=0.01), parasomnias (SMD= 0.68, 95% CI [0.21; 1.15], p=0.02), sleep disordered breathing (SMD=0.34, 95% CI [0.09; 0.59], p=0.02) and total sleep difficulties (SMD=0.92, 95% CI [-0.00; 1.83], p=0.05). All remaining subscales yielded non-significant estimates.

Sleep Efficiency

Of 6 studies that measured sleep efficiency, five reported sleep efficiency via PSG and one used actigraphy, all of which were pooled into the meta-analysis. The random effects model revealed that CWE experience significantly reduced sleep efficiency compared to healthy children (SMD= -0.71, [95% CI [-1.23; -0.19], p=0.02), see Figure 5. CWE had an average sleep efficiency of 83% (compared to controls mean sleep efficiency of 89%). The mean difference was 6% less for CWE and this ranged between 0.2% more to 10% less than controls across studies. There was low heterogeneity amongst the studies ($Q= 8.22$, $I^2= 39.2$, $p=0.14$). Sensitivity and outlier analysis did not reveal any influential cases, confirming the robustness of the results.

Sleep Architecture
Separate meta-analyses were conducted for percentage of sleep stages (see Figure 6): N1% (5 studies), N2% (6 studies), N3% (5 studies) and REM% (6 studies). The meta-analyses initially revealed no significant differences for all sleep stages. Sensitivity analyses was conducted and revealed two outliers [36,38] in N2% and one outlier [38] in N3% and REM%. Removal of all outliers did not have a significant effect on the overall effect size estimate for N3% and REM%. However, when the outliers for N2% were removed, the overall effect size estimate was found to be of borderline significance (SMD=0.44, 95% CI [0.00; 0.87], p=0.05), indicating that CWE had a higher percentage of N2 compared to healthy children. There was no substantial heterogeneity detected ($I^2=0\%$, $Q=1.27$, $p=0.74$), thus no further analyses were conducted.

Heterogeneity Analysis

In order to explore other sources of heterogeneity and their potential impact on the results, subgroup and meta-regression analyses were conducted on the TST, sleep difficulties and sleep efficiency data. Subgroup analyses were performed using categorical variables (type of sleep instrument) and meta-regression analyses were performed using continuous variables (age, % of male individuals and quality of study), to assess whether the overall effect size in the above datasets were impacted by these variables.

Total sleep time

No significant subgroup differences were found between PSG, 24-hour video-EEG, self-report and actigraphy ($Q=3.17; p=0.37$) indicating that the type of sleep measure did not have an effect on TST. The meta regression analyses revealed no significant associations between TST and age ($p=0.79$, $R^2=0\%$), sex ($p=0.89$, $R^2=0\%$) or quality of the study ($p=0.67$, $R^2=0\%$)

Sleep difficulties
No significant subgroup differences were detected between the SBQ and CSHQ on the overall effect size estimates for sleep difficulties ($Q=0.21$, $p=0.64$). The meta-regression analysis found no significant associations between sleep difficulties and age ($p=0.16$, $R^2=22.71\%$), sex ($p=0.33$, $R^2=2.78\%$) or quality of the study ($p=0.15$, $R^2=20.70\%$).

**Sleep Efficiency**

No significant subgroup differences were found between actigraphy or PSG on the overall sleep efficiency estimates ($Q=2.06$, $p=0.15$). The meta-regression analysis found no significant associations between sleep efficiency and age ($p=0.20$, $R^2=37.7\%$), sex ($p=0.10$, $R^2=47.9\%$) or quality of the study ($p=0.09$, $R^2=42.08\%$).

**Publication Bias**

Assessment of publication bias was conducted using a graphical approach and statistical testing when there were $\geq 10$ studies available. For TST the contour enhanced funnel plot indicated some asymmetry. Closer inspection demonstrated that most of the studies fell in the area of non-statistical significance (white shading) rather than the areas of significance (light blue and blue shading), hence the funnel asymmetry was unlikely to be attributed to publication bias [42]. This was confirmed via the Eggers test which revealed a non-significant effect $p=0.17$ (see S1 for funnel plot).

**DISCUSSION**

**Summary of findings**

Sleep difficulties are often reported by parents of CWE, however this relationship continues to be under-recognized clinically. To our knowledge, this is the first meta-analysis to quantify differences across self-reported and objective measures of sleep variables between CWE and healthy children. A wide range of sleep parameters were considered within the meta-analysis including sleep timing, sleep difficulties, sleep efficiency and sleep architecture in order to
incorporate a variety of findings and approaches. In addition, the use of a systematic search strategy with inclusive terms optimised the breadth of literature captured. The use of robust assessments of study quality strengthened the confidence in our findings and, as anticipated, CWE experienced deficits across a wide range of sleep parameters. Our analysis indicated that CWE have significantly reduced TST and sleep efficiency, increased percentage of N2 and more frequent and severe sleep difficulties across various domains compared to healthy children.

Previous research has consistently highlighted that poor sleep in CWE can impact seizure control and also increase the risk of poorer behavioural and psychological outcomes in comparison to healthy children. Therefore, this evidence of sleep disruptions in CWE warrants further investigation and a greater degree of clinical acknowledgment.

Analysis of TST found CWE slept on average 34 minutes less in comparison to healthy children (this ranged from 151 minutes less to 9 minutes more across studies). This meta-analytic finding confirms previous empirical studies [37,43]. It is clinically relevant to the management of CWE, given that insufficient sleep can act as a precipitating factor for IEDs and seizure control. Reduced sleep duration also increases daytime sleepiness which will have an impact on behaviour, learning and overall quality of life (QOL) [44].

Our results also revealed significantly more frequent sleep difficulties in CWE, which were most pronounced in relation to the subscales of night waking, SDB and parasomnias as assessed via the CSHQ. This demonstrates that both objective and subjective measures are consistently highlighting poorer sleep parameters in CWE in comparison to healthy children. Moreover, as sleep difficulties often contribute to and prefigure the development of sleep disorders, they pose a clinical problem in their own right. They should therefore be addressed in order to mitigate the risk of these difficulties worsening and complicating the presentation of the epilepsy.

Sleep difficulties including parasomnias and SDB are commonly observed in CWE [45] and there are various mechanisms underlying these disturbances. NREM parasomnias can be
triggered at times of anxiety, which is heightened in CWE given the unpredictable nature of seizures [46,47]. Additionally, it is important to note that commonly experienced parasomnias such as confusional arousals and night terrors share similar gross semiology and behavioural features to nocturnal seizures [48], which is why video monitoring forms such a crucial part of the diagnostic workflow. It is therefore possible that parent reports are unable to capture this difference in the absence of video-EEG data. SDB in CWE can be attributed to multiple factors including side effect of antiepileptic drugs (AEDs) (see below) and disturbed sleep [49]. SDB has been associated with a range of deficits including alterations to sleep and neurocognitive impairments, and thus presents a risk for the developmental progress of CWE [33].

Our analysis of PSG variables revealed alterations to sleep architecture, specifically increased N2% in CWE compared to healthy children. This may relate to the higher rates of SDB observed, which often results in frequent arousals during sleep, increasing the time children spend within the lighter stages of sleep [50]. Similarly, poor sleep efficiency was also apparent in CWE, averaging 83%, which is below the average of 90% [51] in the healthy population and may be indicative of poor seizure control as suggested by previous research [52].

Interestingly, nearly all studies within the meta-analysis included CWE on AED treatment, which may in part contribute to the differences observed in sleep macro-structure and respiratory parameters. AEDs can have varying effects on sleep architecture and sleep efficiency [53,54]. In addition, polytherapy is found to exacerbate the occurrence of parasomnias [8] and ultimately lead to more severe sleep difficulties in comparison to those on monotherapy [29]. Another side effect of some AEDs is increased weight gain, which is a risk factor for apnoea events during sleep due to the heightened risk of blockages of the upper airways [49,50]. SDB is also associated with dysfunction of the cardiovascular system which is speculated to play a role in sudden unexpected death in epilepsy, highlighting the potentially devastating consequences of
sleep disturbances in CWE [55]. Therefore, consideration of the type of AEDs administered and the possible presence of an underlying sleep disorder is vital in the overall assessment of CWE.

Strengths and Limitations

In the current meta-analysis, strict inclusion criteria were set in order to produce the most reliable findings, which has both strengths and limitations. One strength was the inclusion of studies employing a variety of sleep instruments, as this provides both subjective and objective quantification of sleep disturbances in CWE. This also allowed us to investigate a range of aspects related to sleep, which is important given the complexity of sleep as a behaviour.

Another criterion was only including studies comparing CWE to healthy children. This provided a reference point for understanding the specific sleep disruptions that are present in CWE, but also resulted in the loss of potentially informative studies that did not include a control group. Nonetheless, the findings from studies that were not included as they did not have a control group [43,52,56,57] were consistent with those in the review. They also emphasised the association with behavioural and psychiatric co-morbidities [56,57]. We did not have the scope to examine the impact of psychopathologies on sleep within this meta-analysis, however this is an important area of future research given the importance of these issues to patients.

Similarly, this meta-analysis extends the results of a previous review investigating sleep problems in CWE, by providing the first empirical synthesis of the data [58]. This review highlighted the need for longitudinal designs to be conducted, in order to draw stronger conclusions on the association between sleep and epilepsy. It was also noted that results from parent-report measures are likely to be influenced by their own anxieties. However, the current meta-analysis demonstrates that regardless of whether subjective or objective measures are used, there are clear and consistent differences between CWE and healthy children across sleep parameters.
The majority of included studies combined epilepsy types into one broad group e.g.,
generalised and focal epilepsy. This is particularly problematic given that ictal and interictal
indicators of epilepsy vary with the sleep/wake cycle in a way which is specific to the type of
epilepsy, e.g., focal epilepsies with secondary generalisation are more vulnerable to sleep
disturbances compared to generalised epilepsies [45], while interictal manifestations of focal
epilepsies vary across the sleep-wake cycle [59]. In addition, the underlying neurobiological
basis of some epilepsies may tie in closely with the brain networks involved in sleep generation
and regulation, e.g., the suggestion that generalised spike-wave discharges make use of
thalamocortical networks normally involved in the generation of sleep spindles [60]. These and
other issues concerning the relationship between epilepsy and sleep are discussed in detail in
several reviews [61,62]. Finally sleep disturbances appeared to be more pronounced in those
with drug resistant epilepsy, as supported by previous research [38]. This is to be expected given
the use of multiple AEDs and experience of recurrent uncontrollable seizures, all of which
contribute to disruptions to sleep [63]. However, the relative contribution of AEDs and recurrent
seizures to sleep habits is difficult to disentangle. Furthermore, the lack of reporting on seizure
control using standardised measures meant we did not have the ability to investigate the
influence of this factor. Future studies are needed which are focussed much more closely on
individual epilepsy syndromes in terms of their relationship with sleep, with a specific need for
investigation of paediatric epilepsies, given the importance of adequate sleep for brain
development [64].

Another important factor which has been briefly mentioned above is that across the majority
of included studies, children were receiving AEDs. The majority of AEDs have been established
to impact sleep architecture [45,50], and issues such as drowsiness are commonly experienced
[65]. Despite reporting treatment use, many of the studies failed to subdivide participants by
AED type, and hence we were not able to investigate the impact of AEDs specifically. The fact
that studies of rolandic epilepsy, which is generally not treated with AEDs, showed a similar
tendency to the overall results, suggests that the effects we observed are not entirely the result of
treatment. However, future studies should detail the type and dose of AEDs in order to allow
specific investigation of their impact.

We excluded studies involving co-morbid IDs, on the basis that they would affect
interpretation of the results, making it too difficult to differentiate the effects of epilepsy from the
effects of an ID, which are known to impact sleep [22]. This ultimately led to the exclusion of
studies focussed on the more severe epilepsies e.g., epileptic encephalopathies, which are
typically associated with serious cognitive and neuropsychological deficits. However, in practice
this would suggest that the clinical importance of sleep disturbances across the full range of
epilepsies would be expected to be higher than estimated by our meta-analysis, with our results
representing a lower bound. Nevertheless, previous research investigating sleep habits in
children with ID where epilepsy is prevalent, such as Angelman syndrome and tuberous sclerosis
complex, have demonstrated that the presence of epilepsy in ID can have a cumulative effect on
sleep disturbances [66].

Finally, studies measuring sleep architecture used two different scoring systems for sleep:
Rechtschaffen & Kales (R&K) [67] and American Academy of Sleep Medicine (AASM) [68].
Previous research has found significant differences between the two when measuring children’s
and adolescents’ sleep, including differences in N1, N2 and REM [69]. Unfortunately, sensitivity
analysis could not be conducted to assess the influence of scoring systems, as there were
insufficient studies. This limitation does not affect the majority of the results, and indeed the
effects seen in terms of sleep architecture were generally smaller than for other measures of sleep
disturbance.
Methodological considerations

There are several methodological considerations that may aid with standardisation between studies in the future. The first is that within this meta-analysis, some sleep parameters were extracted from a broad range of measurements including both objective (e.g., actigraphy, PSG) and subjective (e.g., sleep diaries, questionnaires) tools. Within the context of our statistical analysis (see the Heterogeneity Analysis section above), the overall conclusions did not depend on the details of these instruments. Due to the limited number of papers in this area, we believe that including as wide a range of studies as possible and analysing the impact of their heterogeneity statistically was the most favourable approach. However, more broadly, comparing sleep parameters derived from different methodological approaches is not ideal, and points towards the need for more widespread adoption of some standard and widely tolerated tools such as actigraphy and questionnaires within future studies of this type.

In our analyses for sleep problems, the majority of the data were derived from parent report measures. Parents of children with chronic diseases such as epilepsy have heightened parental anxiety and stress, and reports may be influenced by parents’ own perceptions and result in overestimation of problem [70]. Similarly, parents are less involved in their child’s bedtime routines as they grow older, so may be less aware of their sleep patterns, especially in adolescence [71]. Another problem that arises with parent report measures, which has been previously discussed, is the difficulty faced when distinguishing nocturnal seizures from NREM parasomnias. In order to resolve this issue, we recommend that studies should not rely heavily on questionnaire measures in such cases but rather consider videos or preferably video-EEG. Future research should also aim to use parent-proxy measures in younger children and self-reports in older groups or preferably use objective measures such as actigraphy to provide a more accurate measure of habitual sleep patterns. We have previously found that actigraphy is well tolerated, even in children with severe ID [72].
In our analysis of sleep architecture, one study [38] measured percentage of sleep stages in reference to sleep period time whereas the remaining studies used TST. Interestingly, this study was detected as an outlier in sensitivity analysis and when removed, revealed a significant result for percentage of N2. This suggests that the non-significant result was driven by differences in sleep scoring rather than differences in sleep architecture. Other studies were not able to be included in the analysis of some sleep stages due to studies combining stages, which made it difficult to compare them. We recommend that future studies explicitly state what scoring parameters were used for sleep variables and to report sleep stages individually, rather than collating them together e.g., N1+N2. Finally, future studies should specify the type of epilepsy and seizures, and when possible the epilepsy syndromes, aetiology, disease severity and AED use, given the potential influence of these factors in CWE. Introducing such modifications to future studies would result in easier comparison of studies and allow for richer data to be meta-analysed.

Conclusion

This meta-analysis found that CWE suffer from widespread objective and subjective sleep disruptions in comparison to healthy children. Improving the specificity of this finding requires future studies which investigate individual epilepsy syndromes, with standardised subjective and objective sleep markers, and clear reporting of AEDs. At the present time, habitual sleep patterns are not consistently evaluated by specialists in the routine care or diagnosis for CWE, which is likely to be attributed to the complexity of the disease and the primary goal of treating seizures. However, epilepsy is a chronic and unpredictable disease, and the association with sleep disruptions only further negatively impacts the QOL in the child and family. The present results indicate the potential benefit for childhood epileptologist to consider the importance of sleep in epilepsy management. Furthermore, future research should aim to develop behavioural
interventions to tackle sleep difficulties early on in childhood epilepsy in order to reduce the
detrimental impacts the disease and additional co-morbidities may have on developmental
outcomes.

<table>
<thead>
<tr>
<th>Practice points</th>
</tr>
</thead>
</table>
| 1) Children with epilepsy experience both objective and subjective disruptions to their
  sleep in comparison to healthy children that require clinical acknowledgment. |
| 2) Co-occurring intellectual disability were excluded as this group are understood to be at
  an increased risk for sleep disturbances. This raises the possibility that our results
  likely capture the lower estimate of the range of sleep disruptions. It is important that
  clinicians consider the impact of these factors in epilepsy management. |
| 3) Children with drug resistant epilepsy appear to be most vulnerable to sleep
  disturbances, although the relative contribution of anti-epileptic medications or
  recurrent seizures is not clear. |
| 4) Routine screening of sleep habits and the inclusion of a sleep specialist as part of the
  diagnostic process are recommended for children with epilepsy. |
Research Agenda

1) Further studies should place more emphasis on investigating individual epilepsy syndromes with consistent etiologies in order to understand the differences in sleep patterns across epilepsies.

2) Future research should aim to extend current findings to investigate whether poor quality of sleep with co-occurring epilepsy has a greater consequence on quality of life, academic attainment and mental health, than in healthy children.

3) The current studies had various methodological limitations which posed restrictions to extracting and synthesising data. To mitigate this problem, future research should aim to develop standardised sleep questionnaires for paediatric epilepsy patients, to aid in comparing across groups, and ensure routine reporting of AEDs for individual patients.

4) Future research should encourage the use of wearable devices in clinical settings as they provide considerable value in gathering accurate information on sleep habits, which can help to better understand the role in epilepsy.

5) Studies on interventions should be conducted to investigate whether improving sleep habits has an impact on health-related quality of life and seizures.
Conflicts of interest: The authors declare no conflict of interest in relation to this work.

Acknowledgements: This work was supported by the Waterloo Foundation.

Authors contributions

All authors contributed to the manuscript as follows:

Study design and concept: AW, AB, CR.

Acquisition and analysis of data: AW

Interpretation of the data: All authors.

Drafting of the manuscript: All authors.

Approval of the final manuscript: All authors.

APPENDIX A

+-----------------------------------+INSERT FIGURE S1 HERE+-----------------------------------+
REFERENCES*


Takagi S. Sleep and epilepsy. *Sleep and Biological Rhythms* 2017; **15**:189-96.


Tsai SY, Lee WT, Lee CC, Jeng SF, Weng WC. Behavioural-educational sleep interventions for pediatric epilepsy: a randomized controlled trial. *Sleep* 2020; **43**:zsz211.*


Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. *Bmj* 2011; **342**: d549.


Shvarts V, Chung S. Epilepsy, antiseizure therapy, and sleep cycle parameters. Epilepsy research and treatment 2013;2013.*

Jain SV, Glauser TA. Effects of epilepsy treatments on sleep architecture and daytime sleepiness: an evidence-based review of objective sleep metrics. Epilepsia 2014; 55:26-37.


Leresche N, Lambert RC, Errington AC, Crunelli V. From sleep spindles of natural sleep to spike and wave discharges of typical absence seizures: is the hypothesis still valid?. *Pflügers Archiv-European Journal of Physiology* 2012; **463**: 201-12.

Kotagal P, Yardi N. The relationship between sleep and epilepsy. *In Seminars in pediatric neurology* 2008; **15**: 42-49.*

Frauscher B, Gotman J. Sleep, oscillations, interictal discharges, and seizures in human focal epilepsy. *Neurobiology of disease* 2019; **127**: 545-553*


Dahl RE. Sleep and the developing brain. *Sleep* 2007; **30**:1079.


Rechtschaffen A, Kales, A. A manual for standardized terminology, techniques and scoring system for sleep stages in human subjects, editors. Brain Research Institute, UCLA. 1968.


Novelli L, Ferri R, Bruni O. Sleep classification according to AASM and Rechtschaffen and Kales: effects on sleep scoring parameters of children and adolescents. *Journal of sleep research* 2010; **19**:238-47.


Figure Legends

Figure 1. Flowchart of search process

Figure 2. Forest plot for standardised mean difference (Hedge’s g) in sleep time between children with epilepsy and healthy controls. The bold vertical line in the middle represents the line of null effect. Black horizontal lines represent 95% confidence intervals and the squares are the point estimate of the study result. The prediction interval represents the range in which the point estimate of 95% of future studies will be expected to fall in. The diamond at the bottom of the figure plots the overall effect and the corresponding confidence interval.

Figure 3. Forest plot for standardised mean difference (Hedge’s g) in total sleep problems between children with epilepsy and healthy children. The bold vertical line in the middle represents the line of null effect. Black horizontal lines represent 95% confidence intervals and the squares are the point estimate of the study result. The prediction interval represents the range in which the point estimate of 95% of future studies will be expected to fall in. The diamond at the bottom of the figure plots the overall effect and the corresponding confidence interval.

Figure 4. Forest plot for standardised mean difference (Hedge’s g) in type of sleep difficulties on CSHQ between children with epilepsy and healthy children. The bold vertical line in the middle represents the line of null effect. Black horizontal lines represent 95% confidence intervals and the squares are the point estimate of the study result. The prediction interval represents the range in which the point estimate of 95% of future studies will be expected to fall in. The diamond at the bottom of the figure plots the overall effect and the corresponding confidence interval.
**Figure 5.** Forest plot for standardised mean difference (Hedge’s g) in sleep efficiency (%) between children with epilepsy and healthy children. The bold vertical line in the middle represents the line of null effect. Black horizontal lines represent 95% confidence intervals and the squares are the point estimate of the study result. The prediction interval represents the range in which the point estimate of 95% of future studies will be expected to fall in. The diamond at the bottom of the figure plots the overall effect and the corresponding confidence interval.

**Figure 6.** Forest plot for standardised mean difference (Hedge’s g) in percentage of N1, N2, N3 and rapid eye movement sleep between children with epilepsy and healthy children. The bold vertical line in the middle represents the line of null effect. Black horizontal lines represent 95% confidence intervals and the squares are the point estimate of the study result. The prediction interval represents the range in which the point estimate of 95% of future studies will be expected to fall in. The diamond at the bottom of the figure plots the overall effect and the corresponding confidence interval.

**Appendix A:** Supplementary data

**Figure S1:** Contour enhanced funnel plot. Standardised mean difference in total sleep time between children with epilepsy and healthy children plotted against standard errors. Black circles refer to the included studies. The light blue shaded region corresponds to p-values below 0.01, the blue shaded region corresponds to p-values between 0.05 and 0.01, the dark blue shaded region corresponds to p-values between 0.1 and 0.05.
### Table 1. Database search terms

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1</strong></td>
<td><strong>Sleep</strong></td>
</tr>
<tr>
<td></td>
<td>Sleep* or Non 24 hour sleep wake disorder or Non 24 hour sleep wake syndrome or Non 24 hour sleep wake rhythm disorder or Free running disorder or Hypernychthemeral disorder or N24HSWD or Non 24 hour circadian rhythm disorder or somniloquy or sleep talking or night talking or Sub wakefulness Syndrome or hypnagogic hallucination* or confusional arousal* or sleep enuresis or nocturnal enuresis or night enuresis or night* wet* or nocturnal bed wet* or rapid* eye movement behavi* disorder* or REM behavi* disorder* or Nightmare disorder* or dream anxiety disorder* or nightmare syndr* or Non* Rapid Eye Movement Arousal or NREM arousal or Nocturnal eat* or nocturnal drink* or night eat* or night drink* or nocturnal Bruxism or sleep bruxism or nocturnal tooth* or nocturnal teeth* or night* walking or sleep terror* or night* terror* or Parasomni* or Circadian rhythm disorder* or circadian rhythm sleep* or CRSD or Central Alveolar Hypoventilation or central alveolar hypovent* or Central hypoventilat* or Narcolepsy or narcolep* or hypersomnolen* or hypersomni* or insomni* or sleep problems or sleep difficulties or sleep disturbance or sleep disorder or sleepiness or daytime sleepiness or sleep quality or insomnia or sleep apnea or Obstructive sleep apnea or total sleep time or sleep onset latency or Sleep efficiency or sleep onset time or wake or nocturnal or snoring or sleep disordered breathing or restless leg syndrome</td>
</tr>
<tr>
<td><strong>2</strong></td>
<td><strong>Epilepsy</strong></td>
</tr>
<tr>
<td></td>
<td>Childhood epilepsy or epilepsy or epilep* or Epilepsy syndrome or Adolescent epilepsy or paediatric epilepsy or Seizures or west syndrome or infantile spasms or dravet syndrome or Lennox Gastaut syndrome or Doose syndrome or Myoclonic Astatic epilepsy or Progressive myoclonic epilepsy or Benign Rolandic epilepsy or Benign Epilepsy with centro-temporal spikes or Panayiotopoulos syndrome or childhood absence epilepsy or Juvenile myoclonic epilepsy</td>
</tr>
<tr>
<td><strong>3</strong></td>
<td><strong>Childhood</strong></td>
</tr>
<tr>
<td></td>
<td>children or child* or paediatr* or adolescen*</td>
</tr>
<tr>
<td><strong>4</strong></td>
<td>(1 AND 2 AND 3)</td>
</tr>
</tbody>
</table>
Table 2. Quality rating framework.

<table>
<thead>
<tr>
<th></th>
<th>0 – Poor (Red)</th>
<th>1 – Adequate (Orange)</th>
<th>2 – Good (Yellow)</th>
<th>3 – Excellent (Green)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Epilepsy diagnosis</strong></td>
<td>Not specified / reported</td>
<td>Seizure type Focal, generalised or unknown</td>
<td>Epilepsy type Focal, generalised, combined generalised and focal</td>
<td>Epilepsy syndrome Must specify the type of syndrome</td>
</tr>
<tr>
<td><strong>Sample Identification</strong></td>
<td>Not specified / reported</td>
<td>Single restricted or non-random sample (specialist clinic or previous research study)</td>
<td>Multiple restricted or non-random samples (multi-region specialist clinics)</td>
<td>Random or total population sample</td>
</tr>
<tr>
<td><strong>Sleep measurement</strong></td>
<td>Response to a single question</td>
<td>Validated sleep questionnaire. Note any form of validation is applicable (for instance clinician judgement to make adaptations for population)</td>
<td>Self/parent monitoring through diaries</td>
<td>Polysomnography (following at least 1 day for adaptation) Actigraphy of 7 days or more</td>
</tr>
</tbody>
</table>
### Table 3. Study characteristics

<table>
<thead>
<tr>
<th>Study</th>
<th>Sample size</th>
<th>Age(Y, mean)</th>
<th>Sex (male%)</th>
<th>Diagnosis</th>
<th>Sleep measure</th>
<th>Sleep variable</th>
<th>Medication</th>
<th>Adaptation night</th>
<th>Quality criteria</th>
<th>Overall quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barreto et al, 2002[28]</td>
<td>10 13</td>
<td>12.2 8.9</td>
<td>40 54</td>
<td>10 Idiopathic generalised epilepsy 13 Benign epilepsy with centrotemporal spikes 21 Focal seizures 28 Focal seizures with secondary generalisation 32 Generalised seizures</td>
<td>PSG</td>
<td>TST, N1, N2, N3, N4, REM% 74% on AEDs</td>
<td>No</td>
<td>3 1 2</td>
<td>0.67</td>
<td></td>
</tr>
<tr>
<td>Batista &amp; Nunes 2007[29]</td>
<td>81 81</td>
<td>9.3 9.3</td>
<td>48 N/A</td>
<td>21 Focal seizures 28 Focal seizures with secondary generalisation 32 Generalised seizures</td>
<td>SBQ</td>
<td>SBQ total score 27.1% polytherapy</td>
<td>N/A</td>
<td>1 1 1</td>
<td>0.33</td>
<td></td>
</tr>
<tr>
<td>Bruni et al, 2010 [30]</td>
<td>10 10</td>
<td>8.1 7.8</td>
<td>N/A N/A</td>
<td>10 Rolandic epilepsy</td>
<td>PSG</td>
<td>TST, SE(%), N1, N2, N3, REM% Unknown</td>
<td>Yes</td>
<td>3 1 3</td>
<td>0.78</td>
<td></td>
</tr>
<tr>
<td>Byars et al, 2008 [8]</td>
<td>332 321</td>
<td>9.6 9.6</td>
<td>49 48</td>
<td>Various epilepsy syndromes</td>
<td>SBQ</td>
<td>Parent reported sleep time SBQ total score 62% monotherapy 25% polytherapy</td>
<td>N/A</td>
<td>3 2 1</td>
<td>0.67</td>
<td></td>
</tr>
<tr>
<td>Chan et al, 2011 [31]</td>
<td>63 169</td>
<td>8.4 7.7</td>
<td>49 49</td>
<td>40 Generalised epilepsy 23 Partial epilepsy</td>
<td>CSHQ</td>
<td>CSHQ total score 100% monotherapy</td>
<td>N/A</td>
<td>2 2 1</td>
<td>0.56</td>
<td></td>
</tr>
<tr>
<td>Chan et al, 2017 [32]</td>
<td>22 21</td>
<td>11.5 10.6</td>
<td>64 43</td>
<td>Focal epilepsy</td>
<td>PSG</td>
<td>TST, N1, N2, N3, REM% Yes (% unknown)</td>
<td>No</td>
<td>2 1 2</td>
<td>0.56</td>
<td></td>
</tr>
<tr>
<td>Cortesi et al, 1999 [18]</td>
<td>89 48</td>
<td>9.7 9.2</td>
<td>56 48</td>
<td>63 Primary generalised epilepsy 26 Primary partial epilepsy</td>
<td>SBQ</td>
<td>SBQ total score</td>
<td>100% monotherapy</td>
<td>N/A</td>
<td>2 1 1</td>
<td>0.44</td>
</tr>
<tr>
<td>Ekinci et al, 2016 [16]</td>
<td>53 28</td>
<td>11.8 12.14</td>
<td>55 61</td>
<td>24 Partial seizures 16 Generalised-tonic clonic seizures 13 Absence seizures 22 Generalised epilepsy 18 Focal epilepsy</td>
<td>CSHQ</td>
<td>CSHQ total score and subscales 77% Monotherapy</td>
<td>N/A</td>
<td>1 1 1</td>
<td>0.33</td>
<td></td>
</tr>
<tr>
<td>Gogou et al, 2016 [33]</td>
<td>40 27</td>
<td>10.6 11</td>
<td>N/A N/A</td>
<td>22 Generalised epilepsy 18 Focal epilepsy</td>
<td>PSG</td>
<td>TST, N3, N1+N2, N3, REM% 80% Monotherapy</td>
<td>No</td>
<td>2 1 2</td>
<td>0.56</td>
<td></td>
</tr>
<tr>
<td>Gogou et al, 2017 [34]</td>
<td>15 27</td>
<td>10.5 11</td>
<td>N/A N/A</td>
<td>Rolandic Epilepsy</td>
<td>PSG</td>
<td>TST, SE(%), N1+N2, N3, REM% 73.3% Monotherapy</td>
<td>No</td>
<td>3 1 2</td>
<td>0.67</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Sample Size</td>
<td>Gender</td>
<td>Age (mean)</td>
<td>Duration (mean)</td>
<td>Epilepsy Type</td>
<td>Measures</td>
<td>AED Use</td>
<td>Polytherapy</td>
<td>REM %</td>
<td>Outcome</td>
</tr>
<tr>
<td>------------------------------</td>
<td>-------------</td>
<td>--------</td>
<td>------------</td>
<td>----------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>---------</td>
<td>-------------</td>
<td>-------</td>
<td>----------</td>
</tr>
<tr>
<td>Holley et al, 2014 [35]</td>
<td>23</td>
<td>50</td>
<td>10</td>
<td>9.3</td>
<td>Childhood absence epilepsy, generalised tonic clonic seizures, focal seizures and not known</td>
<td>CSHQ Actigraphy, CSHQ total score and subscales Actigraphy</td>
<td>96% on AEDs</td>
<td>N/A</td>
<td>3</td>
<td>0.89</td>
</tr>
<tr>
<td>Maganti et al, 2005 [9]</td>
<td>11</td>
<td>8</td>
<td>13.4</td>
<td>14.3</td>
<td>5 Childhood absence, 4 juvenile absence, 2 juvenile myoclonic epilepsy</td>
<td>PSG TST, SE(%), N1, N2, N3, REM%</td>
<td>Yes</td>
<td></td>
<td>3</td>
<td>0.78</td>
</tr>
<tr>
<td>Maganti et al, 2006 [6]</td>
<td>26</td>
<td>26</td>
<td>14.6</td>
<td>14.7</td>
<td>14 Idiopathic generalised epilepsy 12 Localisation related epilepsy</td>
<td>PDSS PSQ Parent reported sleep duration</td>
<td>100% on AEDs</td>
<td>N/A</td>
<td>3</td>
<td>0.56</td>
</tr>
<tr>
<td>Myatchin &amp; Lagae 2007 [36]</td>
<td>6</td>
<td>47</td>
<td>9.7</td>
<td>8.6</td>
<td>4 Childhood absence, 1 myoclonic absence, 1 juvenile myoclonic epilepsy</td>
<td>24-hour Video-EEG TST, N2%</td>
<td>No</td>
<td></td>
<td>3</td>
<td>0.67</td>
</tr>
<tr>
<td>Nunes et al, 2003 [37]</td>
<td>17</td>
<td>11</td>
<td>4.7-16.2</td>
<td>7.17-18.8</td>
<td>3 Idiopathic localisation related epilepsy 14 Symptomatic localisation related epilepsy</td>
<td>PSG TST, N1, N2, N3-N4%, REM%</td>
<td>Yes</td>
<td></td>
<td>3</td>
<td>0.78</td>
</tr>
<tr>
<td>Pereira et al, 2012 [38]</td>
<td>8</td>
<td>23</td>
<td>11.9</td>
<td>8.3</td>
<td>5 Idiopathic localisation related epilepsy 3 Symptomatic localisation related epilepsy</td>
<td>PSG TST, SE(%), N1, N2, N3 and REM%</td>
<td>No</td>
<td></td>
<td>3</td>
<td>0.56</td>
</tr>
<tr>
<td>Shaheen et al, 2012 [39]</td>
<td>26</td>
<td>12</td>
<td>12.6</td>
<td>11.8</td>
<td>4 Generalised epilepsy 12 Focal epilepsy 10 Focal epilepsy with secondary generalisation Rolandic epilepsy</td>
<td>PSG TST, SE(%), N1%, N2%, N3%, REM%</td>
<td>No</td>
<td></td>
<td>2</td>
<td>0.56</td>
</tr>
<tr>
<td>Tang et al, 2011 [40]</td>
<td>43</td>
<td>494</td>
<td>9.8</td>
<td>7.6</td>
<td>Reported but not quantified for subgroup</td>
<td>CSHQ CSHQ total and subscales</td>
<td>31% treated with AEDs</td>
<td>N/A</td>
<td>3</td>
<td>0.67</td>
</tr>
<tr>
<td>Wirrell et al, 2005 [41]</td>
<td>26</td>
<td>55</td>
<td>N/A</td>
<td>N/A</td>
<td>Reported but not quantified for subgroup</td>
<td>SBQ SBQ total</td>
<td>N/A</td>
<td></td>
<td>3</td>
<td>0.56</td>
</tr>
</tbody>
</table>

**Abbreviations:** AEDs = Anti-epileptic drugs, CSHQ = Children's sleep habits questionnaire, EEG = Electroencephalography, PDSS = Paediatric daytime sleepiness scale, PSG = Polysomnography, PSQ = Paediatric sleep questionnaire, REM = Rapid eye movement, SBQ = Sleep behaviour questionnaire, SE = Sleep efficiency, TST = Total sleep time.
Records identified through database search (PubMed=3068) (PsychINFO=934) (Medline=3940) (Embase=7009)

Additional records identified through other sources (n = 0)

Duplicates removed (n = 6113)

Records screened (n = 8838)

Records excluded (n = 8619)

Full-text articles assessed for eligibility (n = 219)

Studies included in reported parameters meta-analysis (n = 19)

Full-text articles excluded, with reasons (n = 200)

Reasons for exclusion:

- No healthy control (44)
- No sleep measures (14)
- No paediatric patients (44)
- Not English language (18)
- Wrong publication type e.g., review, abstract, case studies, editorials (54)
- Patients with an intellectual disability (7)
- Data not presented in format suitable for analysis (7)
- Inappropriate population (2)
- Inappropriate measure (2)
- No author response (3)
- Paper unavailable (5)
### Study Random effects model

**Prediction interval**

Heterogeneity: $I^2 = 82\%$, $\tau^2 = 0.6091$, $p < 0.01$

<table>
<thead>
<tr>
<th>Study</th>
<th>Experimental</th>
<th>Control</th>
<th>Standardised Mean Difference</th>
<th>SMD</th>
<th>95%–CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>Mean</td>
<td>SD</td>
<td>Total</td>
<td>Mean</td>
<td>SD</td>
<td></td>
</tr>
<tr>
<td>Barreto et al., (2002) [28]</td>
<td>10 368.75</td>
<td>75.9900</td>
<td>12 388.29</td>
<td>51.9200</td>
<td></td>
<td>-0.29</td>
</tr>
<tr>
<td>Bruni et al., (2010) [30]</td>
<td>10 444.40</td>
<td>74.3500</td>
<td>10 507.20</td>
<td>38.4500</td>
<td></td>
<td>-1.02</td>
</tr>
<tr>
<td>Chan et al., (2011) [31]</td>
<td>63 560.70</td>
<td>70.5000</td>
<td>164 557.10</td>
<td>73.5000</td>
<td></td>
<td>0.05</td>
</tr>
<tr>
<td>Cortestì et al., (1999) [18]</td>
<td>89 555.00</td>
<td>50.0000</td>
<td>321 560.00</td>
<td>41.0000</td>
<td></td>
<td>-0.12</td>
</tr>
<tr>
<td>Gogou et al., (2016) [33]</td>
<td>40 402.00</td>
<td>45.0000</td>
<td>27 414.00</td>
<td>42.6000</td>
<td></td>
<td>-0.27</td>
</tr>
<tr>
<td>Holley et al., (2014) [35]</td>
<td>23 469.32</td>
<td>46.4100</td>
<td>50 466.58</td>
<td>51.4100</td>
<td></td>
<td>-0.34</td>
</tr>
<tr>
<td>Maganti et al., (2005) [9]</td>
<td>11 449.09</td>
<td>53.9700</td>
<td>8 446.28</td>
<td>29.8400</td>
<td></td>
<td>0.06</td>
</tr>
<tr>
<td>Myatchin &amp; Lagae (2007) [36]</td>
<td>6 526.30</td>
<td>88.8000</td>
<td>47 523.20</td>
<td>65.5000</td>
<td></td>
<td>0.04</td>
</tr>
<tr>
<td>Nunes et al., (2003) [37]</td>
<td>17 370.43</td>
<td>64.9500</td>
<td>11 521.00</td>
<td>39.5000</td>
<td></td>
<td>-2.59</td>
</tr>
<tr>
<td>Pereira et al., (2012) [38]</td>
<td>8 391.75</td>
<td>48.7300</td>
<td>23 512.80</td>
<td>60.3600</td>
<td></td>
<td>-2.04</td>
</tr>
<tr>
<td>Tang et al., (2011) [40]</td>
<td>43 566.40</td>
<td>77.4000</td>
<td>494 609.00</td>
<td>39.0000</td>
<td></td>
<td>-0.98</td>
</tr>
</tbody>
</table>

**Total** 346 1193

**SMD** $-0.55$ [−1.08; −0.02] **Weight** 100.0%

**95%–CI** $[-2.37; 1.27]$
Random effects model

Prediction interval

Heterogeneity: $I^2 = 88\%$, $\tau^2 = 0.2943$, $p < 0.01$

Chan et al., (2011) [31] 63 48.89 6.8300 169 44.10 6.4300
Ekinci et al., (2016) [16] 53 52.59 6.3300 28 43.21 2.8500
Holley et al., (2014) [35] 22 43.09 5.4100 50 43.47 6.3500
Tang et al., (2011) [40] 43 42.42 5.8800 494 38.71 5.5100
Wirrell et al., (2005) [41] 26 48.00 12.0000 55 40.00 9.0000

Total

646

332

321

Mean

54.20

48.89

44.10

SD

13.5000

6.8300

6.4300

Control

1185

321

43.09

6.3300

Weight

14.3%

13.6%

9.8%

13.1%

11.7%

12.0%

13.5%

12.1%

Random effects model

646

1185

0.97 [ 0.48; 1.46] 100.0%

[−0.45; 2.39]
Residual heterogeneity:

- Measure = CSHQ Total
  - Holley et al., (2014) [35]
  - Ekinci et al., (2016) [16]
  - Chan et al., (2011) [31]
- Measure = Daytime Sleepiness
  - Holley et al., (2014) [35]
  - Ekinci et al., (2016) [16]
  - Chan et al., (2011) [31]
- Measure = Sleep Anxiety
  - Holley et al., (2014) [35]
  - Ekinci et al., (2016) [16]
  - Chan et al., (2011) [31]
- Measure = Night Waking
  - Holley et al., (2014) [35]
  - Ekinci et al., (2016) [16]
  - Chan et al., (2011) [31]
<table>
<thead>
<tr>
<th>Study</th>
<th>Experimental Total</th>
<th>Mean</th>
<th>SD</th>
<th>Control Total</th>
<th>Mean</th>
<th>SD</th>
<th>Standardised Mean Difference</th>
<th>SMD</th>
<th>95%–CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bruni et al., (2010)</td>
<td>10 87.70</td>
<td>5.8300</td>
<td>10</td>
<td>93.20</td>
<td>3.8900</td>
<td></td>
<td>−1.06</td>
<td>−2.01</td>
<td>−0.19</td>
<td>12.9%</td>
</tr>
<tr>
<td>Gogou et al., (2017)</td>
<td>15 82.00</td>
<td>11.0000</td>
<td>27</td>
<td>88.00</td>
<td>8.0000</td>
<td></td>
<td>−0.64</td>
<td>−1.29</td>
<td>0.00</td>
<td>19.1%</td>
</tr>
<tr>
<td>Holley et al., (2014)</td>
<td>23 83.82</td>
<td>7.7700</td>
<td>50</td>
<td>86.20</td>
<td>6.8200</td>
<td></td>
<td>−0.33</td>
<td>−0.83</td>
<td>0.17</td>
<td>23.2%</td>
</tr>
<tr>
<td>Maganti et al., (2005)</td>
<td>11 90.86</td>
<td>5.1500</td>
<td>8</td>
<td>90.66</td>
<td>3.7200</td>
<td></td>
<td>0.04</td>
<td>−0.87</td>
<td>0.95</td>
<td>13.5%</td>
</tr>
<tr>
<td>Pereira et al., (2012)</td>
<td>8 82.66</td>
<td>12.3000</td>
<td>23</td>
<td>92.60</td>
<td>5.3900</td>
<td></td>
<td>−1.27</td>
<td>−2.14</td>
<td>−0.39</td>
<td>14.2%</td>
</tr>
<tr>
<td>Shaheen et al., (2012)</td>
<td>26 73.17</td>
<td>7.3300</td>
<td>12</td>
<td>83.12</td>
<td>10.5900</td>
<td></td>
<td>−1.15</td>
<td>−1.89</td>
<td>−0.41</td>
<td>17.0%</td>
</tr>
</tbody>
</table>

**Total** 93 130

**Random effects model**

- **Predicted interval**

Heterogeneity: $I^2 = 39\%$, $\tau^2 = 0.1489$, $p = 0.14$
### 1. N1%

<table>
<thead>
<tr>
<th>Study</th>
<th>Experimental Total</th>
<th>Mean</th>
<th>SD</th>
<th>Control Total</th>
<th>Mean</th>
<th>SD</th>
<th>Standardised Mean Difference</th>
<th>SMD</th>
<th>95%–CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barreto et al., (2002) [28]</td>
<td>10 4.79 3.93000</td>
<td></td>
<td></td>
<td>12 2.36 2.16000</td>
<td></td>
<td></td>
<td></td>
<td>0.76</td>
<td>[−0.12; 1.63]</td>
<td>18.7%</td>
</tr>
<tr>
<td>Bruni et al., (2010) [30]</td>
<td>10 9.40 3.56000</td>
<td></td>
<td></td>
<td>10 9.40 3.76000</td>
<td></td>
<td></td>
<td></td>
<td>0.00</td>
<td>[−0.88; 0.88]</td>
<td>18.7%</td>
</tr>
<tr>
<td>Maganti et al., (2005) [9]</td>
<td>11 7.19 3.27000</td>
<td></td>
<td></td>
<td>8 4.87 2.58000</td>
<td></td>
<td></td>
<td></td>
<td>0.74</td>
<td>[−0.21; 1.69]</td>
<td>16.6%</td>
</tr>
<tr>
<td>Pereira et al., (2012) [38]</td>
<td>8 8.67 8.29000</td>
<td></td>
<td></td>
<td>23 3.80 3.85000</td>
<td></td>
<td></td>
<td></td>
<td>0.90</td>
<td>[0.06; 1.74]</td>
<td>19.9%</td>
</tr>
<tr>
<td>Shaheen et al., (2012) [29]</td>
<td>26 8.18 7.18000</td>
<td></td>
<td></td>
<td>12 7.22 6.86000</td>
<td></td>
<td></td>
<td></td>
<td>0.13</td>
<td>[−0.55; 0.82]</td>
<td>26.2%</td>
</tr>
</tbody>
</table>

Random effects model: 65
Prediction interval
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0.0710$, $p = 0.44$

### 2. N2%

<table>
<thead>
<tr>
<th>Study</th>
<th>Experimental Total</th>
<th>Mean</th>
<th>SD</th>
<th>Control Total</th>
<th>Mean</th>
<th>SD</th>
<th>Standardised Mean Difference</th>
<th>SMD</th>
<th>95%–CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barreto et al., (2002) [28]</td>
<td>10 53.25 12.6700</td>
<td></td>
<td></td>
<td>12 50.11 7.39000</td>
<td></td>
<td></td>
<td></td>
<td>0.30</td>
<td>[−0.55; 1.14]</td>
<td>24.0%</td>
</tr>
<tr>
<td>Bruni et al., (2010) [30]</td>
<td>10 44.50 10.4600</td>
<td></td>
<td></td>
<td>10 42.10 4.84000</td>
<td></td>
<td></td>
<td></td>
<td>0.28</td>
<td>[−0.60; 1.16]</td>
<td>22.2%</td>
</tr>
<tr>
<td>Maganti et al., (2005) [9]</td>
<td>11 49.49 8.90000</td>
<td></td>
<td></td>
<td>8 47.46 8.02000</td>
<td></td>
<td></td>
<td></td>
<td>0.23</td>
<td>[−0.69; 1.14]</td>
<td>20.7%</td>
</tr>
<tr>
<td>Shaheen et al., (2012) [29]</td>
<td>26 57.01 17.1200</td>
<td></td>
<td></td>
<td>12 44.05 14.9800</td>
<td></td>
<td></td>
<td></td>
<td>0.77</td>
<td>[0.06; 1.48]</td>
<td>33.1%</td>
</tr>
</tbody>
</table>

Random effects model: 57
Prediction interval
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0.0153$, $p = 0.74$

### 3. N3%

<table>
<thead>
<tr>
<th>Study</th>
<th>Experimental Total</th>
<th>Mean</th>
<th>SD</th>
<th>Control Total</th>
<th>Mean</th>
<th>SD</th>
<th>Standardised Mean Difference</th>
<th>SMD</th>
<th>95%–CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bruni et al., (2010) [30]</td>
<td>10 27.50 6.06000</td>
<td></td>
<td></td>
<td>10 26.20 3.29000</td>
<td></td>
<td></td>
<td></td>
<td>0.26</td>
<td>[−0.63; 1.14]</td>
<td>19.4%</td>
</tr>
<tr>
<td>Gogou et al., (2016) [33]</td>
<td>40 32.00 10.48000</td>
<td></td>
<td></td>
<td>27 30.69 6.89000</td>
<td></td>
<td></td>
<td></td>
<td>0.14</td>
<td>[−0.35; 0.63]</td>
<td>22.3%</td>
</tr>
<tr>
<td>Maganti et al., (2005) [9]</td>
<td>11 17.33 5.45000</td>
<td></td>
<td></td>
<td>8 17.31 5.77000</td>
<td></td>
<td></td>
<td></td>
<td>0.00</td>
<td>[−0.91; 0.91]</td>
<td>19.2%</td>
</tr>
<tr>
<td>Pereira et al., (2012) [38]</td>
<td>8 9.37 9.12000</td>
<td></td>
<td></td>
<td>23 23.70 5.31000</td>
<td></td>
<td></td>
<td></td>
<td>−2.17</td>
<td>[−3.16; −1.18]</td>
<td>18.5%</td>
</tr>
<tr>
<td>Shaheen et al., (2012) [39]</td>
<td>26 23.11 10.2700</td>
<td></td>
<td></td>
<td>12 36.08 14.9000</td>
<td></td>
<td></td>
<td></td>
<td>−1.07</td>
<td>[−1.80; −0.34]</td>
<td>20.6%</td>
</tr>
</tbody>
</table>

Random effects model: 95
Prediction interval
Heterogeneity: $I^2 = 83\%$, $\tau^2 = 0.8664$, $p < 0.01$

### 4. REM%

<table>
<thead>
<tr>
<th>Study</th>
<th>Experimental Total</th>
<th>Mean</th>
<th>SD</th>
<th>Control Total</th>
<th>Mean</th>
<th>SD</th>
<th>Standardised Mean Difference</th>
<th>SMD</th>
<th>95%–CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barreto et al., (2002) [28]</td>
<td>10 24.92 8.22000</td>
<td></td>
<td></td>
<td>12 22.71 7.40000</td>
<td></td>
<td></td>
<td></td>
<td>0.27</td>
<td>[−0.57; 1.12]</td>
<td>16.6%</td>
</tr>
<tr>
<td>Gogou et al., (2016) [33]</td>
<td>40 18.63 5.88000</td>
<td></td>
<td></td>
<td>27 21.24 4.65000</td>
<td></td>
<td></td>
<td></td>
<td>−0.48</td>
<td>[−0.97; 0.02]</td>
<td>19.1%</td>
</tr>
<tr>
<td>Maganti et al., (2005) [9]</td>
<td>11 17.91 3.84000</td>
<td></td>
<td></td>
<td>8 22.03 7.93000</td>
<td></td>
<td></td>
<td></td>
<td>−0.67</td>
<td>[−1.61; 0.27]</td>
<td>15.8%</td>
</tr>
<tr>
<td>Pereira et al., (2012) [38]</td>
<td>8 9.73 5.79000</td>
<td></td>
<td></td>
<td>23 22.96 5.04000</td>
<td></td>
<td></td>
<td></td>
<td>−2.45</td>
<td>[−3.49; −1.42]</td>
<td>15.1%</td>
</tr>
<tr>
<td>Shaheen et al., (2012) [39]</td>
<td>26 12.57 9.33000</td>
<td></td>
<td></td>
<td>12 12.62 6.28000</td>
<td></td>
<td></td>
<td></td>
<td>−0.01</td>
<td>[−0.69; 0.68]</td>
<td>17.8%</td>
</tr>
</tbody>
</table>

Random effects model: 105
Prediction interval
Heterogeneity: $I^2 = 76\%$, $\tau^2 = 0.7432$, $p < 0.01$
Figure

A scatter plot showing the standardised mean difference (x-axis) against standard error (y-axis). The points are color-coded based on the significance level: 0.1 > p > 0.05 (clear), 0.05 > p > 0.01 (blue), and p < 0.01 (dark blue).